Search International and National Patent Collections

1. (WO2017184427) TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS AND OLIGONUCLEOTIDE FORMULATIONS

Pub. No.:    WO/2017/184427    International Application No.:    PCT/US2017/027417
Publication Date: Fri Oct 27 01:59:59 CEST 2017 International Filing Date: Fri Apr 14 01:59:59 CEST 2017
IPC: A61K 9/127
A61K 9/00
A61P 27/02
A61K 31/7088
Applicants: EXICURE, INC.
Inventors: PATEL, Pinal
ANDERSON, Bart
Title: TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS AND OLIGONUCLEOTIDE FORMULATIONS
Abstract:
Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof. The formulations may include an inhibitor such as an inhibitor of tumour necrosis factor alpha (TNFa), platelet-derived growth factor subunit A (PDGFA), platelet-derived growth factor subunit B (PDGFB), platelet-derived growth factor subunit C (PDGFC), platelet-derived growth factor subunit D (PDGFD), platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), platelet-derived growth factor receptor like (PDGFRL), vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth factor D (VEGFD), vascular endothelial growth factor receptor- 1 (VEGFRl), vascular endothelial growth factor receptor-2 (VEGFR2), vascular endothelial growth factor receptor-3 (VEGFR3), beta-2 adrenergic receptor (ADRB2), connective tissue growth factor (CTGF), interleukin 1 beta (IL1 β), interleukin 1 receptor-1 (IL1 R1), interleukin 1 receptor-2 (IL1R2), and interleukin 1 receptor-3 (IL1R3). Aspects of the invention further relate to nanostructures comprising self-assembling therapeutic oligonucleotides, such as antisense oligonucleotides, that are linked to a molecular species, wherein the molecular species is positioned in a core of the nanostructure and the oligonucleotides extend radially from the core.